ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Entry into a Material Definitive Agreement

ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

On November22, 2017, Rockwell Medical,Inc. (the “Company”) entered into a Settlement and Standstill Agreement (the “Settlement Agreement”) with Richmond Brothers,Inc., Mark H. Ravich, who currently serves as a director of the Company, and the other persons identified on Appendix A thereto (collectively, the “Shareholder Group”), to settle claims made by the parties in an action filed in the United States District Court for the Eastern District of Michigan (the “Litigation”). The Settlement Agreement provides, among other things, that:

· The parties mutually release each other with respect to all claims based on any matter occurring prior to the date of the Settlement Agreement.

· The parties will jointly request dismissal of the Litigation with prejudice.

· The Company will reimburse the Shareholder Group for documented third-party expenses incurred in connection with the Litigation and/or the proxy contest related to the 2017 Annual Meeting of Shareholders in an aggregate amount not to exceed $895,000.

· The Shareholder Group, until the earlier of (a)December31, 2018 or (b)30 days prior to the deadline established to the Company’s Bylaws for the submission of shareholder nominations for directors at the 2019 Annual Meeting of Shareholders (the “Covered Period”), agrees to cause any securities of the Company which it is entitled to vote to be present and generally to be voted at any meeting of shareholders (including the 2018 Annual Meeting of Shareholders): (i)in favor of each director nominated by the Company’s Board of Directors (the “Board”) for election at such meeting; (ii)against any proposals or resolutions to remove any member of the Board (unless supported by the Board); and (iii)in accordance with the Board’s recommendations for each and every other proposal by the Board subject to a shareholder vote at such meeting; provided, however, the Shareholder Group will be permitted to vote in accordance with recommendations (other than the election or removal of directors, or a plan for equity-based compensation that is an Independent Director Approved Plan (as defined in the Settlement Agreement)) made by the proxy advisory firms identified in the Settlement Agreement in the event the recommendations by both of the identified firms are contrary to the Board’s recommendations and will be permitted to vote in its sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition of all or substantially all of the assets of the Company or other business combination involving the Company requiring a vote of shareholders of the Company.

· The Shareholder Group will be bound by various standstill provisions during the Covered Period limiting its ability to, among other things, solicit proxies, act in concert with third parties, seek to effect or facilitate an acquisition of the Company, call a special meeting, seek to cause shareholders to take action by consent without a shareholders meeting, initiate or encourage litigation against the Company, take certain governance-related actions, purchase additional shares of Company stock above certain limitations, or make certain public statements or disclosures.

· The Board will add one additional director by February15, 2018 (the “Additional Director”). In the event the Board does not add the Additional Director by that date, the persons identified in the Settlement Agreement as the “Richmond Group” may nominate directors by February 28, 2018 for election at the 2018 Annual Meeting of Shareholders.

· John G. Cooper, who currently serves as a member of the Board, or the Additional Director will be named as Lead Independent Director by February15, 2018.

· A new Chairperson of the Company’s Governance and Nominating Committee will be appointed no later than December7, 2017.

· During the Covered Period, the Board may not increase in size beyond seven members without the approval of at least four Board members.

· The parties will not disparage each other.

The foregoing summary does not purport to be a complete description of the terms of the Settlement Agreement and is qualified in its entirety by reference to the full text of the Settlement Agreement, a copy of which is attached hereto as Exhibit10.72.

Item 9.01. Financial Statements and Exhibits.

EX-10.72 2 a17-27693_1ex10d72.htm EX-10.72 Exhibit 10.72   SETTLEMENT AND STANDSTILL AGREEMENT   This Settlement and Standstill Agreement (the “Agreement”),…
To view the full exhibit click here


Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

An ad to help with our costs